Works by Jianhua Chang


Results: 65
    1
    2
    3
    4
    5
    6

    Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial.

    Published in:
    Supportive Care in Cancer, 2014, v. 22, n. 4, p. 979, doi. 10.1007/s00520-013-2043-9
    By:
    • Hu, Zhihuang;
    • Cheng, Ying;
    • Zhang, Hongyu;
    • Zhou, Caicun;
    • Han, Baohui;
    • Zhang, Yiping;
    • Huang, Cheng;
    • Chang, Jianhua;
    • Song, Xiangqun;
    • Liang, Jun;
    • Liang, Houjie;
    • Bai, Chunxue;
    • Yu, Shiying;
    • Chen, Jia;
    • Wang, Jie;
    • Pan, Hongming;
    • Chitkara, Denesh;
    • Hille, Darcy;
    • Zhang, Li
    Publication type:
    Article
    7
    8

    Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3‐day aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study

    Published in:
    Cancer Medicine, 2020, v. 9, n. 14, p. 5134, doi. 10.1002/cam4.3123
    By:
    • Chang, Jianhua;
    • Chen, Gongyan;
    • Wang, Dong;
    • Wang, Guihua;
    • Lu, Shun;
    • Feng, Jifeng;
    • Li, Wei;
    • Li, Ping;
    • Lanzarotti, Corinna;
    • Chessari, Salvatore;
    • Zhang, Li
    Publication type:
    Article
    9
    10
    11
    12
    13
    14
    15
    16

    A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.

    Published in:
    Targeted Oncology, 2022, v. 17, n. 1, p. 1, doi. 10.1007/s11523-021-00859-6
    By:
    • Tu, Hai-Yan;
    • Feng, Jifeng;
    • Shi, Meiqi;
    • Zhao, Jun;
    • Wang, Yuyan;
    • Chang, Jianhua;
    • Wang, Jialei;
    • Cheng, Ying;
    • Zhu, Jing;
    • Tan, Eng-Huat;
    • Li, Kai;
    • Zhang, Yiping;
    • Lee, Victor;
    • Yang, Cheng-Ta;
    • Su, Wu-Chou;
    • Lam, David Chi-Leung;
    • Srinivasa, B. J.;
    • Rajappa, Senthil;
    • Ho, Ching-Liang;
    • Lam, Kwok Chi
    Publication type:
    Article
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38

    An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870).

    Published in:
    Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221138380
    By:
    • Lu, Shun;
    • Cheng, Ying;
    • Zhou, Jianying;
    • Wang, Mengzhao;
    • Zhao, Jun;
    • Wang, Baocheng;
    • Chen, Gongyan;
    • Feng, Jifeng;
    • Ma, Zhiyong;
    • Wu, Lin;
    • Wang, Changli;
    • Ma, Kewei;
    • Zhang, Shucai;
    • Liang, Jun;
    • Song, Yong;
    • Wang, Jie;
    • Wu, Yi-Long;
    • Li, Ang;
    • Huang, Yizhi;
    • Chang, Jianhua
    Publication type:
    Article
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49

    A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/Cisplatin and Gemcitabine/Cisplatin as First-line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer.

    Published in:
    Chinese Journal of Lung Cancer, 2012, v. 15, n. 10, p. 576, doi. 10.3779/j.issn.1009-3419.2012.10.03
    By:
    • Yan Huang;
    • Yunpeng Liu;
    • Jianying Zhou;
    • Nong Xu;
    • Baolan Li;
    • Gang Wu;
    • Jian Fang;
    • Kai Li;
    • Xiaoqing Liu;
    • Wei Liu;
    • You Lu;
    • Mengzhao Wang;
    • Wenchao Liu;
    • Houjie Liang;
    • Yiping Zhang;
    • Cheng Huang;
    • Shunjin Wang;
    • Yajie Wang;
    • Shiying Yu;
    • Jianhua Chang
    Publication type:
    Article
    50